ArticleACS omega2025
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biochemical-knowledge-driven machine learning pipeline for generating potent antimicrobial peptides.Briefings in bioinformatics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance (AMR) poses a critical global health threat, driven largely by the misuse of antibiotics and the emergence of multidrug-resistant (MDR) pathogens. Antimicrobial peptides (AMPs) have emerged as promising alternatives to traditional antibiotics due to their broad-spectrum activity and low propensity for inducing resistance. This study presents the design, synthesis, and characterization of a novel fusion peptide, WMRK-gH625, which combines the antimicrobial activity of peptide WMR-K with the membrane-translocating capability of cell-penetrating peptide gH625. The hybrid peptide exhibited a helical conformation, enhanced membrane fusion and destabilization capabilities, and selective action against bacterial membranes without significant effects on eukaryotic cells. WMRK-gH625 demonstrated potent antimicrobial activity against both Gram-positive bacteria, including
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.